Stocks
Fate Therapeutics (FATE) EV/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -12.1 | -56.8 | -23.9 | -2.21 | -0.91 | -0.34 | ||
| Changes by years, y/y, % | +47% | +370% | -58% | -91% | -59% | -35.7% | |||
Fate Therapeutics. EV/EBITDA
Fate Therapeutics. EV/EBITDA, changes, %
Fate Therapeutics (FATE) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EV/EBITDA | ? | 0.19 | -0.93 | -2.42 | -1.05 | -1.20 | -0.34 | |
| Changes by years, y/y, % | -103% | -57% | +137% | +23% | -749% | |||
| Changes by quarters, q/q, % | -122% | -605% | +159% | -57% | +15% | |||
